Interventions: Drug: Deucravacitinib; Drug: Ustekinumab
Sponsors: Bristol-Myers Squibb
Not yet recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Interventions: Drug: Deucravacitinib; Drug: Ustekinumab
Sponsors: Bristol-Myers Squibb
Not yet recruiting
Es gibt noch keine Rezensionen.